New York, N.Y., USA - Synergy Pharmaceuticals announced that it has appointed Timothy Callahan and Richard Daly as new independent directors.
Article continues below
Mr. Callahan is a global life sciences business leader with mor than 21 years of experience in pharmaceutical and biologic commercialization, most recently with the Actavis organization.
From 2013-2014 Mr. Callahan served as Senior Vice President, Commercial Operations where he played a leadership role in the transformation of the Actavis brand business into a division with a focus in Gastroenterology, Women's Health, Urology, Dermatology, and other specialty markets.
From 2010-2012, Mr. Callahan served as Vice President, International Brands & Biologics Marketing at Actavis, and from 2003-2009 he served as Vice President, Sales & Marketing for the company's Nephrology division.
Earlier in his career, Mr. Callahan held positions of increasing responsibility in commercial leadership at Watson Pharmaceuticals and Schein Pharmaceutical.
Mr. Callahan was educated at Cornell University and holds a Bachelor of Science degree in Applied Economics and Business Management.
Mr. Daly has more than 20 years of commercial pharmaceutical experience working in positions of progressive responsibility in sales, marketing and operations.
Recently, Mr. Daly was the President of U.S. Diabetes for the joint alliance between Bristol-Myers Squibb and AstraZeneca.
In the past, Mr. Daly was a founding partner and board member of SagePath Partners LLC, a commercial outsourcing provider to the pharmaceutical industry that was sold to Ashfield Commercial & Medical Services in 2013.
During his 13-year tenure at Takeda Pharmaceuticals, he served as Executive Vice President with P&L responsibility for businesses across the U.S., Canada, and Central/South America.
Earlier in his career, Mr. Daly has served in the sales organizations at Merrell-Dow Pharmaceuticals (now part of Sanofi) and TAP Pharmaceuticals (formerly a division of Abbott Labs) in sales, marketing, operations and senior leadership positions at TAP and Takeda.
He currently serves on the board of Catalyst Pharmaceuticals and Andean Health & Development. ■